Literature DB >> 2963363

Butoctamide hydrogen succinate and intensive learning sessions: effects on night sleep of Down's syndrome patients.

G L Gigli1, J C Grubar, R M Colognola, M T Amata, C Pollicina, R Ferri, S A Musumeci, P Bergonzi.   

Abstract

Mentally retarded children present a reduction in percentage of REM sleep and of oculomotor frequencies. These sleep patterns are probably relevant for their cognitive activities. The effects of butoctamide hydrogen succinate and intensive learning sessions on the night sleep of five Down's syndrome patients was studied by the authors. They found an increase in percentage of REM sleep after pharmacological treatment and an increase in oculomotor frequencies after learning sessions. The authors' hypotheses of REM sleep as a neurophysiological indicator of cerebral "plasticity" and of oculomotor frequencies as an indicator of "organization" abilities are discussed in this article. Pedagogical implications and therapeutical perspectives are also outlined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963363     DOI: 10.1093/sleep/10.6.563

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  3 in total

Review 1.  Sleep measurement and monitoring in children with Down syndrome: a review of the literature, 1960-2010.

Authors:  Shervin S Churchill; Gail M Kieckhefer; Carol A Landis; Teresa M Ward
Journal:  Sleep Med Rev       Date:  2012-03-10       Impact factor: 11.609

2.  Long-term administration of butoctamide hydrogen succinate on nocturnal sleep of mentally retarded subjects: a polygraphic study versus placebo.

Authors:  G L Gigli; J C Grubar; P Bergonzi; M C Maschio
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

3.  Sleep-like behavior and 24-h rhythm disruption in the Tc1 mouse model of Down syndrome.

Authors:  I Heise; S P Fisher; G T Banks; S Wells; S N Peirson; R G Foster; P M Nolan
Journal:  Genes Brain Behav       Date:  2015-02-16       Impact factor: 3.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.